About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker RBGLY · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Dec 30, 2020Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute…
NCT01202279 · Acute Upper Respiratory Track Infection
Guaifenesin, Placebo
RBGLY
Reckitt Benckiser Inc.
Phase 4Completed1,179Apr 2010Registry ↗
Dec 30, 2020Mucinex Exploratory Cold Study
NCT01046136 · Common Cold
guaifenesin (Mucinex), placebo
RBGLY
Reckitt Benckiser Inc.
Phase 2Completed378Mar 2010Registry ↗
Jun 20, 2019Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate
NCT03642873 · Healthy Subjects
Humibid®, Hydrocodone Bitartrate
RBGLY
Reckitt Benckiser LLC
Phase 1Completed24May 21, 2007Registry ↗
Jun 19, 2019Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifen…
NCT03644095 · Healthy Subjects
Mucinex® SE, Vicks Cough Syrup for Chesty Coughs
RBGLY
Reckitt Benckiser Inc.
Phase 1Completed30Feb 1, 2009Registry ↗
Jun 17, 2019Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4h
NCT03642262 · Healthy Subjects
Mucinex®
RBGLY
Reckitt Benckiser Inc.
Phase 1Completed30Aug 9, 2013Registry ↗
Jun 17, 2019Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and Adolescents
NCT03633448 · Healthy Subjects
Children's Mucinex® Grape Flavor, Children's Mucinex® Grape…
RBGLY
Reckitt Benckiser LLC
Phase 1Completed24Jul 1, 2011Registry ↗
Mar 27, 2019Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted
NCT03649750 · Healthy Subjects
Mucinex®
RBGLY
Reckitt Benckiser LLC
Phase 1Completed36Aug 7, 2013Registry ↗
Mar 27, 2019Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in…
NCT03643575 · Healthy Subjects
Vicks Cough Syrup for Chesty Coughs, Robitussin Extra Stren…
RBGLY
Reckitt Benckiser Inc.
Phase 1Completed30Jul 16, 2009Registry ↗
Mar 19, 2019Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-L…
NCT03725085 · Healthy Subjects
Mucinex™ extended-release (SE)
RBGLY
Reckitt Benckiser LLC
Phase 4Completed552Oct 16, 2015Registry ↗
Feb 28, 2019Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Health…
NCT03644108 · Healthy Subjects
Mucinex® ER 600 mg
RBGLY
Reckitt Benckiser Inc.
Phase 1Completed30Jun 15, 2009Registry ↗
Feb 28, 2019Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet
NCT03633487 · Healthy Subjects
Mucinex®
RBGLY
Reckitt Benckiser LLC
Phase 1Completed24Oct 15, 2011Registry ↗
Sep 19, 2018Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respirat…
NCT01114581 · Acute Respiratory Infection
Mucinex, Placebo
RBGLY
Reckitt Benckiser LLC
Phase 2Completed38Apr 2011Registry ↗
Sep 17, 2018Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study
NCT01229449 · Post-operative Pain
Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher do…
RBGLY
Reckitt Benckiser LLC
Phase 3Completed678Sep 2009Registry ↗
Oct 11, 2017Safety & Performance Study of Verruca Treatment Device
NCT01536834 · Verruca, Plantar Wart
Medical Device
RBGLY
Reckitt Benckiser LLC
Not applicableCompleted35Jan 2013Registry ↗
Sep 28, 2017Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
NCT01986361 · Acute Pharyngitis, Sore Throat
flurbiprofen, placebo
RBGLY
Reckitt Benckiser LLC
Phase 3Completed122Apr 2014Registry ↗
Sep 21, 2017A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis
NCT01049334 · Pharyngitis
Placebo, Flurbiprofen
RBGLY
Reckitt Benckiser LLC
Phase 3Completed204Mar 2011Registry ↗
Sep 21, 2017A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis
NCT01048866 · Pharyngitis
placebo, flurbiprofen
RBGLY
Reckitt Benckiser LLC
Phase 3Completed198Mar 2011Registry ↗
Sep 11, 2017Evaluation of Tolerance and Acceptability of a Coated Condom
NCT01619397 · Tolerance and Acceptability of a New Condom Coating
Test condom with new Xanthan gum condom coating
RBGLY
Reckitt Benckiser LLC
Not applicableCompleted50Oct 2012Registry ↗

18 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:52 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances